课题基金 / 基金详情

Evolution of DNA restriction endonucleases and the creation of new endonucleases for DNA manipulation.

Evolution of DNA restriction endonucleases and the creation of new endonucleases for DNA manipulation.
DNA 限制性核酸内切酶的进化以及用于 DNA 操作的新核酸内切酶的创建。
批准号:
BB/K005804/1
负责人:
David Dryden
金额:
$75.24万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2013
资助国家:
英国
项目状态:
已结题
起止时间:
2013 至 --

项目摘要

项目成果

David Dryden的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Genetic engineering, essential to the progress of all current biological research, would be impossible without a class of catalysts termed restriction enzymes. These allow the cutting and pasting of segments of DNA to test hypotheses and to create novel routes to vital healthcare products such as insulin. Arguably, it is fair to say that nothing in modern biology, biotechnology and biomedical research would be possible without them. The number of restriction enzymes known is large and many have been commercialised. However new enzymes are still being sought and new uses for them are still being invented. We have recently solved the structure of the first restriction enzyme to be discovered and purified in 1968. These "Type I" restriction enzymes have not so far had impact on healthcare, research or wealth creation despite their abundance in natural populations of bacteria and their impact on slowing down the transfer of DNA encoding, for example, antibiotic resistance and the creation of "superbugs". However our new structure shows how Type I restriction enzymes can be converted into valuable products for research and healthcare. Since thousands of Type I restriction enzymes are known to exist, this ability to convert them promises a veritable bonanza of new and useful restriction enzymes. We propose to perform this conversion process on the Type I restriction enzymes. As well as aiding new research these new enzymes may well prove valuable new tools for gene targeting and editing; a relatively new area studying the genetics of complex organisms particularly with an emphasis on understanding and eventually treating human genetic diseases.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.bbrc.2014.04.162
发表时间: 2014-06
期刊: Biochemical and biophysical research communications
影响因子: 3.1
作者: [Long Ma;Xiaohua Wu;G. Wilson;Anita C Jones;D. Dryden]
通讯作者: Long Ma;Xiaohua Wu;G. Wilson;Anita C Jones;D. Dryden
DOI: 10.1093/nar/gkt990
发表时间: 2014-01
期刊: Nucleic acids research
影响因子: 14.9
作者: [Loenen WA, Dryden DT, Raleigh EA, Wilson GG, Murray NE]
通讯作者: Murray NE
DOI: 10.1093/nar/gkx067
发表时间: 2017-04-07
期刊: Nucleic acids research
影响因子: 14.9
作者: [Cooper LP, Roberts GA, White JH, Luyten YA, Bower EKM, Morgan RD, Roberts RJ, Lindsay JA, Dryden DTF]
通讯作者: Dryden DTF
DOI: 10.1093/nar/gkt847
发表时间: 2014-01
期刊: Nucleic acids research
影响因子: 14.9
作者: [Loenen WA, Dryden DT, Raleigh EA, Wilson GG]
通讯作者: Wilson GG
6
    Adventurous combinations of research knowledge (ACORN)
    • 批准号:
      EP/D056756/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $13.17万
    • 财政年份:
      2006
    • 负责人:
      David Dryden
    • 依托单位:
    国内基金
    海外基金
    自供能传感阵列同步量化游离DNA与PSA实现前列腺癌的诊断和预后判断
    • 批准号:
      JCZRLH202601177
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    二氢杨梅素通过线粒体代谢重编程抑制DNA同源重组修复逆转口腔癌细胞放疗抵抗的机制研究
    • 批准号:
      2026JJ80500
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      阳帆
    • 依托单位:
    乳酸通过ESM1-Akt-MDM2-p53通路调控卵巢癌DNA损伤和抗肿瘤免疫应答的分子机制研究
    • 批准号:
      2026JJ81975
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      肖娇
    • 依托单位:
    淫羊藿苷通过TET2介导DNA去甲基化调控Hippo-YAP/TAZ通路逆转绝经后骨质疏松症成血管-成骨耦联失衡的机制研究